Article
Oncology
Ryosuke Ono, Kosuke Takayama, Fuminori Sakurai, Hiroyuki Mizuguchi
Summary: The study developed a novel OAd fully composed of OAd35, which recognizes CD46 as an infection receptor and showed efficient cell lysis activities similar to OAd5 in CAR-positive tumor cells, while exhibiting higher levels of cell lysis activities than OAd5 in CAR-negative tumor cells. OAd35 had lower proportions of neutralizing antibodies in adults compared to Ad5.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Biochemistry & Molecular Biology
Victor A. Naumenko, Daniil A. Vishnevskiy, Aleksei A. Stepanenko, Anastasiia O. Sosnovtseva, Anastasiia A. Chernysheva, Tatiana O. Abakumova, Marat P. Valikhov, Anastasiia Lipatova, Maxim A. Abakumov, Vladimir P. Chekhonin
Summary: Hepatotoxicity is a problem in adenovirus cancer therapy, caused by Kupffer cell death and hepatocyte transduction. The interaction between adenovirus and liver cells is not well understood. This study used intravital microscopy to track the infection and immune response in mouse livers after adenovirus injection, and found that Ad5-RGD and Ad5/3 caused macrophage deformation and virus release, but neutrophils and CD8+ T cells did not affect the rate or dynamics of liver infection. Ad5-RGD failed to complete the replicative cycle in hepatocytes, but enhanced liver transduction during hepatic regeneration.
Article
Oncology
Tatiana Kudling, James H. A. Clubb, Dafne C. A. Quixabeira, Joao M. Santos, Riikka Havunen, Alexander Kononov, Camilla Heinio, Victor Cervera-Carrascon, Santeri Pakola, Saru Basnet, Susanna Gronberg-Vaha-Koskela, Victor Arias, Ivan Gladwyn-Ng, Katri Aro, Leif Back, Jari Rasanen, Ilkka Ilonen, Kristian Borenius, Mikko Rasanen, Otto Hemminki, Antti Rannikko, Anna Kanerva, Johanna Tapper, Akseli Hemminki
Summary: The study demonstrates that arming an oncolytic adenovirus with Interleukin 7 can effectively decrease tumor growth and increase immune cell infiltration in the tumor microenvironment. This approach offers a potential solution to overcome the limitations of conventional Interleukin 7 therapy and may have clinical implications.
Review
Oncology
Marti Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino, Ramon Alemany
Summary: Cancer immunotherapy utilizing immune checkpoint inhibitors has shown effectiveness in various human cancers, but cold tumors often lack immune cells and are typically unresponsive. Oncolytic viruses, with their lytic and immunogenic mechanisms, have attracted interest as potential therapeutic approaches to heat or promote lymphocyte infiltration of cold tumors. This article reviews the use of oncolytic adenoviruses in cancer immunotherapy, focusing on immune responses triggered by these viruses against tumor antigens in preclinical and clinical settings, as well as considerations for clinical trial design and combination therapies with conventional treatments or other immunotherapies.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Bo-Kyeong Jung, Young Jun Kim, JinWoo Hong, Han-Gyu Chang, A-Rum Yoon, Chae-Ok Yun
Summary: Cancer is a complex and deadly disease with limited treatment options. Targeted therapy using small interfering RNA (siRNA) to silence cancer-enriched proteins is a powerful tool, but its application is limited. Oncolytic adenovirus-mediated therapy offers an alternative approach. This study reports the development of two oncolytic adenovirus systems that effectively and persistently target ErbB3.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Fang Dai, Peng-Bo Zhang, Qiang Feng, Xin-Yan Pan, Shu-Ling Song, Jing Cui, Ju-Lun Yang
Summary: A novel strategy combining oncolytic adenovirus with CIK cells for treating Ras-driven liver cancer was developed. The in vivo study showed significantly inhibited tumor growth with little effect on normal organs, indicating relative safety.
Article
Multidisciplinary Sciences
Hiromichi Matsugo, Tomoya Kitamura-Kobayashi, Haruhiko Kamiki, Hiroho Ishida, Wataru Sekine, Akiko Takenaka-Uema, Takayuki Nakagawa, Shin Murakami, Taisuke Horimoto
Summary: This study explored the use of a bat adenovirus as an oncolytic virus candidate for canine tumors, showing promising results. By creating a recombinant virus with enhanced tumor specificity by inserting a tumor-specific promoter, superior growth and cytotoxicity in canine tumor cells were achieved, indicating potential for alternative canine cancer therapies.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Jing Wang, Shuting Zuo, Yan Zhang, Shanzhi Li, Ying Shi, Tonghua Du, Jicheng Han, Ningyi Jin, Yiquan Li, Xiao Li
Summary: The combination of Ad-VT and cyclophosphamide reduces toxicity and exhibits increased efficacy in treating breast cancer cells.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Oncology
Ryosuke Ono, Kosuke Takayama, Rika Onishi, Sora Tokuoka, Fuminori Sakurai, Hiroyuki Mizuguchi
Summary: This study aimed to evaluate the potential of oncolytic adenoviruses as a treatment for pancreatic cancer. They found that the commonly used adenovirus serotype 5 (Ad5) had limitations due to decreased receptor expression and neutralizing antibodies. As an alternative, an adenovirus serotype 35 (Ad35) was developed, which recognized a specific receptor on pancreatic cancer cells and had fewer neutralizing antibodies.
ANTICANCER RESEARCH
(2023)
Article
Genetics & Heredity
Keqing Lu, Fang Wang, Baoliang Ma, Wenjuan Cao, Qi Guo, Hanzhang Wang, Ronald Rodriguez, Zhiping Wang
Summary: This study aimed to evaluate the teratogenic toxicity of bladder cancer-specific oncolytic adenovirus on mice. It found that the adenovirus did not have any discernable effects on fetal mice and F1 development, suggesting it is relatively safe for tumor gene therapy.
CURRENT GENE THERAPY
(2021)
Review
Biotechnology & Applied Microbiology
Thavasyappan Thambi, JinWoo Hong, A-Rum Yoon, Chae-Ok Yun
Summary: Polymer-complexed adenoviruses can enhance tumor-specific delivery and antitumor activity, but challenges remain in systemic administration and intratumoral retainment of the virus.
CANCER GENE THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Yaomei Tian, Daoyuan Xie, Li Yang
Summary: Oncolytic viruses (OVs) are a potentially useful treatment method for tumors, as they can selectively kill tumor cells without harming healthy cells and enhance antitumor immunity through inducing innate and adaptive immune responses. Genetic engineering of OVs to express immune regulators, as well as their combination with other immunotherapies, has shown promising progress in cancer treatment.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Review
Oncology
Hee Yeon Lee, In Sook Woo
Summary: The development of cytotoxic chemotherapy, targeted agents, and immune checkpoint inhibitors has significantly improved survival outcomes and quality of life in patients with metastatic colorectal cancer. Complete resection of resectable liver metastases can lead to long-term survival and cure, while the benefits of adjuvant chemotherapy after resection are still uncertain. Preoperative systemic treatment can potentially convert unresectable liver metastases to resectable tumors, but the optimal treatment strategy is yet to be established.
Article
Chemistry, Medicinal
Meiru Song, Ge Liu, Yichang Liu, Ziwei Cheng, Haili Lin, Jianyong Liu, Zaisheng Wu, Jinping Xue, Wanjin Hong, Mingdong Huang, Jinyu Li, Peng Xu
Summary: This study proposes a strategy to address the limitations of AMPs as antitumor agents by conjugating them with porphyrins, which bind to albumin and enhance the antitumor efficacy of AMPs. The conjugation also reduces the fast renal clearance and systemic toxicities of AMPs, confirming the design strategy's success.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Koki Sato, Masahiro Ohira, Yuki Imaoka, Kouki Imaoka, Tomoaki Bekki, Marlen Doskali, Ryosuke Nakano, Takuya Yano, Yuka Tanaka, Hideki Ohdan
Summary: This study found that partial hepatectomy can alter the characteristics and function of liver-resident natural killer (lr-NK) cells in the liver, and the AhR molecule is involved in these changes. Treatment with the AhR agonist FICZ increased the proportion of immature NK cells with high TRAIL activity and decreased the proportion of mature NK cells with low TRAIL activity. The involvement of AhR promoted FoxO1 expression in the mTOR signaling pathway, resulting in TRAIL expression.